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Overview
• The problem of small asymptomatic stones
• Background and risks
• Historical data
• How to screen for small stones
• Treatment and waiver
Small and Asymptomatic
• Small calcifications difficult to detect
• What is their significance?
• Parenchymal or in the collecting system
• Stable or growing
• Treat asymptomatic ditzels?
• Or Leave them there?
• How to monitor over time?
Natural History
Size (mm) Stone Free Progression Intervention
<= 5 28% 40.4% 5.3%
5 - 10 4.8% 52.4% 9.5%
>= 10 0% 71.4% 14.3%
Koh, et al. (2011), Outcomes of long-term follow-up of patients with conservative 
management of asymptomatic renal caliculi, BJU Int, 109:622-625.
Spontaneous Passage versus Stone Size
(Ueno, et al. (1977), Relation of spontaneous passage of ureteral calculi to size, Urology, 10(6):544-546.)
General Population
• Lifetime prevalence 10% male, 5% female
• Increasing incidence (20 - 74 y.o.)
• 3.2% to 5.2% (+ male)
• 3.7 % to 4.6% of commercial aviation 
pilots between 2000 – 2007 2
1. Hall, P. (2009) Nephrolithiasis: Treatment, causes and prevention, Clev Clin J Med, 76(10):583-591
2. Hyams, E., et al. (2011) The incidence of urolithiasis among commercial aviation pilots, J Uro, 186:914-916.
IMM Renal Stone Risk
Probability (%)
DRM
No 
Events
Any 
Event
Best 
Case
Worst 
Case
Lunar
(21 Days)
99.979 0.021 0.013 0.003
ISS
(6 months)
99.818 0.182 0.110 0.072
Mars
(3 years)
99.092 1.090 0.659 0.430
IMM Data Request #:  D-20150911-334
LSAH / EMR Review, April 2014
•At least 19 astronauts affected
•3 females, 16 males
•Treatment and prevention varied
•Monitoring parameters varied
LSAH Review, July 2015
# of Events
Long
Duration
Short
Duration
Preflight 4
R+0-90 days 1 1
R+90-180 days 3 1 2
R+180-270 days 1 1
R+270-365 days 2 2
Inter-flight 4 1 3
R>365 days 21 21
Grand Total 36 3 29
How to Screen?
• Language matters
• Mineralized renal material or stone?
• Ultrasound!
• No radiation
• Almost as good as CT
• CT for possible stones
• Flexible Ureteroscopy
• Both diagnosis and treatment
• What use are urine studies?
Sensitivity (%) Specificity (%) Dose (mSv)
Ultrasound
Average 2.6mm (1 – 9 mm, SD 1.15), n=51 pts, 114 stones [17]
Shadowing alone 65 (PPV 90) - 0
Twinkling alone 81 (PPV 94) - 0
Shadowing + Twinkle 88 (PPV 96) - 0
Average 3.9mm ( 1-20 mm), n=105 pts, 65 stones, CT as reference [18]
Shadowing alone 48 (PPV 81) 99 0
Shadowing + Twinkle 55 (PPV 67) 99 0
X-Ray
KUB 45 - 58 69 - 77 0.7
IVP 85 90 3
CT
Low-dose, non-con. 97 95 3
Non-contrast 95 – 98 96 - 98 10
MRI
93 - 100 95 - 100 0
When to Screen?
Enhanced U/S Protocol
1. Echogenic  seen from 2 or more angles
2. Twinkling  frequency dispersion / “twinkling”
3. Shadowing  opaque to ultrasound
4. Localizable  papilla/collecting system
5. Measurable  >= 3 mm


Clinical Practice Guideline
• Use of specialized ultrasound protocol
• Yearly ultrasound for all astronauts??
• MRM by ultrasound may require…
• Low-dose, high resolution CT
• MRM by CT…
• then Flexible Ureteroscopy??
• Mission assignment affects treatment method
• Potential waivers for very small, stable MRM
US Navy Standards
• Waivers given for...
• calcium oxalate, calcium phosphate, uric acid 
and struvite; 
• retained stones in the renal parenchyma; 
• recurrent stones > 12 months apart.
• Medical evaluation & urology consult required
US Navy Standards
• Waivers NOT given for...
• recurrent stones within one year, 
• cysteine stones, 
• hypercalcuria, 
• stones retained in the collecting system. 
Ureteral Stone Size and Time to Passage
Miller and Kane (1999), Time to stone passage for observed ureteral calculi: A guide for patient education, 
J. Urology, 162:688-691.
Exploration Missions?
Back-Up
IMM – Renal Stone Events
DRM** 
Probability Per Mission of One or More Event (%) 
Any Event (95% CI) Best Case (95% CI) 
 
Worst Case (95%) 
Lunar (21 day) 
0.021  (0.017 – 0.026) 0.0127  (0.0074 – 0.019) 
 
0.003  (0.0033 – 
0.014) 
ISS (6 month) 
0.182  (0.149 – 0.222) 0.110  (0.064 – 0.165) 
 
0.072  (0.029 – 
0.122) 
Mars (3 year) 
1.090  (0.887 – 1.320) 0.659 (0.383 – 0.986)  
0.430  (0.172 – 
0.730) 
 
Application Stone Free Pros Cons
best for renal 
or ureteral 
stones <5 mm
<5 mm // 28% do no harm
time, stone 
growth (50%)
Koh, et al. (2011), Outcomes of long-term follow-up of patients with conservative 
management of asymptomatic renal calculi, BJU Int, 109:622-625.
Watch and Wait*
Application Stone Free Pros Cons
best for distal 
ureteral 
stones 
<4 mm // 
55%
a bit better
than waiting
need for 
treatment
Moe, et al. (2011), Pharmacotherapy of urolithiasis: evidence from clinical 
trials, Kidney Intl., 79:385-392. 
Medical Expulsive Therapy
Application Stone Free Pros Cons
best for renal 
stones 10-20 
mm
23 - 82% depend 
on size and 
location, better 
w/ MET
non-
invasive, 
widely 
available
Radiation, no 
better for 
small stones, 
retained frags
Images from: www.kidneystoners.org
Obek, et al., (2001), The efficacy of extracorporeal 
shock wave lithotripsy for isolated lower pole calculi 
compared with isolated middle and upper caliceal 
calculi, J Urol, 166:2081-2085.
Lithotripsy (ESWL)
Application
Stone 
Free
Pros Cons
Can be used 
for any stone
>90%
high-stone 
free rate, low 
retreat rate
less widely 
available, 
operator 
dependent
Images from: www.kidneystoners.org
Hussain, et al. (2011), 
Redefining the limits of flexible 
ureterorenoscopy, J Endourol, 
25(1):45-49.
Flexible Ureteroscopy**
Application Stone Free Pros Cons
large, 
complicated, 
staghorn, other
>95%
definitive 
treatment
invasive, 
serious 
complications 
possible
Images from: www.kidneystoners.org
Breda, et al. (2011), Flexible 
uretroscopy and laser lithotripsy for 
single intrarenal stones 2 cm or 
greater - is this the new frontier?, J 
Urol, 179:981-984
Nephrostomy
